Lumida
/AUPH
⌘K
Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

AUPH
$16.10USD-0.06%-0.01 today

MARKET CAP

2.1B

P/E (TTM)

7.5x

FWD P/E

DAY RANGE

$16 – $16

52W RANGE

$10
$19

AI Summary

Stalk
Buy NowMedium

We see a constructive medium-term backdrop underpinned by a Bullish Pivot Point pattern signaling failed downside control and upward mean reversion. Price is pulling back into the 50-day SMA and converged 9/20 EMAs, offering a disciplined entry near rising support. The long-term trend remains bullish under a rising 200-day SMA. We recommend Buy Now to capitalize on the pullback interaction at key moving averages.

  • Total 2025 revenue reached $283.1M, up 20% YoY.
  • Q4 Lupkinis sales surged 29% to $74.2M.
  • FDA information request fuels regulatory uncertainty.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$45.6M$134.0M$175.5M$235.1M$283.1M
YoY %-9.0%+193.9%+31.0%+34.0%+20.4%
P / Sales64.9x6.3x7.1x5.6x7.8x
EV / Sales61.2x6.1x7.8x6.0x8.1x
Gross Profit, Adj.$44.5M$128.4M$161.4M$206.9M$250.4M
YoY %-11.2%+188.4%+25.7%+28.2%+21.0%
Margin %97.6%95.8%91.9%88.0%88.5%
EV / Gross Profit62.7x6.3x8.5x6.8x9.2x
EBITDA, Adj.$-178.0M$-108.8M$-80.0M$37.9M$126.0M
YoY %-72.9%+38.9%+26.4%+147.3%+232.8%
Margin %-390.3%-81.1%-45.6%16.1%44.5%
EV / EBITDA-15.7x-7.5x-17.2x37.0x18.3x
EBIT$-180.7M$-111.5M$-91.7M$-4.7M$104.9M
YoY %-73.3%+38.3%+17.7%+94.9%+2338.4%
Margin %-396.3%-83.2%-52.2%-2.0%37.1%
EV / EBIT-15.4x-7.3x-15.0x-299.2x21.9x
Net Income$-181.0M$-108.2M$-78.0M$5.8M$287.2M
YoY %-76.2%+40.2%+27.9%+107.4%+4893.1%
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (GAAP)-$1.40-$0.76-$0.54$0.04$2.07
YoY %-60.9%+45.7%+28.9%+107.4%+5075.0%